Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil Daud

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Seminars in Oncology|November 25, 2015
Current and Emerging Perspectives on Immunotherapy for MelanomaAdil Daud
Immunotherapy|June 29, 2016
Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanomaKimberly Loo, Adil Daud
Expert Opinion on Drug Safety|April 9, 2016
Pembrolizumab for melanoma- safety profile and future trendsAdil Daud, Prachi Nandoskar
Human Vaccines & Immunotherapeutics|March 2, 2018
The gut microbiota and immune checkpoint inhibitorsAudrey Humphries, Adil Daud
The Oncologist|May 21, 2017
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic MelanomaAdil Daud, Katy Tsai
Oncology (Williston Park, N.Y.)|May 19, 2016
A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination ApproachLawrence Chen, Adil Daud
Cancer Immunology Research|June 1, 2023
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?Alexandra Haugh, Adil Daud
Human Vaccines & Immunotherapeutics|November 16, 2012
Plasmid IL-12 electroporation in melanomaEdward Cha, Adil Daud
Current Topics in Microbiology and Immunology|August 10, 2011
Beyond BRAF in melanomaAdil Daud, Boris C Bastian
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Management of a patient with advanced BRAF-mutant melanomaMichelle T Ashworth, Adil Daud
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Seminars in Oncology|November 25, 2015
Current and Emerging Perspectives on Immunotherapy for MelanomaAdil Daud
Immunotherapy|June 29, 2016
Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanomaKimberly Loo, Adil Daud
Expert Opinion on Drug Safety|April 9, 2016
Pembrolizumab for melanoma- safety profile and future trendsAdil Daud, Prachi Nandoskar
Human Vaccines & Immunotherapeutics|March 2, 2018
The gut microbiota and immune checkpoint inhibitorsAudrey Humphries, Adil Daud
The Oncologist|May 21, 2017
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic MelanomaAdil Daud, Katy Tsai
Oncology (Williston Park, N.Y.)|May 19, 2016
A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination ApproachLawrence Chen, Adil Daud
Cancer Immunology Research|June 1, 2023
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?Alexandra Haugh, Adil Daud
Human Vaccines & Immunotherapeutics|November 16, 2012
Plasmid IL-12 electroporation in melanomaEdward Cha, Adil Daud
Current Topics in Microbiology and Immunology|August 10, 2011
Beyond BRAF in melanomaAdil Daud, Boris C Bastian
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Management of a patient with advanced BRAF-mutant melanomaMichelle T Ashworth, Adil Daud
Pageof 11